The short version of vaccine adjuvant fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
A surgical drain is a tube used to remove pus, blood or other fluids from a wound, body cavity, or organ. They are commonly placed by surgeons or interventional radiologists after procedures or some types of injuries, but they can also be used as an intervention for decompression. There are several types of drains, and selection of which to use often depends on the placement site and how long the drain is needed.
=== Health === In 2019, she was admitted to a local hospital after complaining of severe pain and illness. It was later revealed that she had caught a life-threatening bacterial infection, which was treated immediately. In February 2021, she underwent a removal of her breast implants and discussed her reason for choosing to remove her implants a year later in a YouTube video. In September 2024, Pansino posted an update on social media stating that she had been diagnosed with premenstrual dysphoric disorder (PMDD). She shared that it had been causing disruptions in her life that at times, had caused her to cancel all plans for weeks and that her symptoms had sent her to the emergency room twice. She also mentioned that she was working with a hormone specialist for treatment. In September 2025, Pansino posted an update on Facebook that her symptoms of PMDD were worsening to the point of causing disruptions in her daily life. As part of her post, she stated, "Recently, my own PMDD symptoms have gotten much worse and it has completely disrupted my ability to have a normal life. I am working with professionals to get onto a new treatment plan." She also posted that she was going to take a break from social media to focus on her treatment and that she intended to make an educational video on PMDD. In June 2025, Pansino posted on social media that she had a benign growth removed from her clavicle after finding the growth the previous year and having undergone an inconclusive biopsy.
She entrusts to scientists the task of continuing to investigate, so that satisfactory answers may be found to the questions connected with this Sheet." John Paul II showed himself to be deeply moved by the image of the Shroud and arranged for public showings in 1998 and 2000. In his address at Turin Cathedral on Sunday 24 May 1998 (the occasion of the 100th year of Secondo Pia's 28 May 1898 photograph), he said: "The Shroud is an image of God's love as well as of human sin... The imprint left by the tortured body of the Crucified One, which attests to the tremendous human capacity for causing pain and death to one's fellow man, stands as an icon of the suffering of the innocent in every age." On 30 March 2013, as part of the Easter celebrations, there was an exposition of the shroud in the Cathedral of Turin. Pope Francis recorded a video message for the occasion, in which he described the image on the shroud as "this Icon of a man", and stated that "the Man of the Shroud invites us to contemplate Jesus of Nazareth". In his carefully worded statement, Francis urged the faithful to contemplate the Shroud with awe, but "stopped firmly short of asserting its authenticity". Pope Francis went on a pilgrimage to Turin on 21 June 2015, to pray before and venerate the Holy Shroud and honour St. John Bosco on the bicentenary of his birth.
At the Tsurugaoka Hachiman-gū's shrine in the city of Kamakura, Kanagawa Prefecture, Japan, an ancient ginkgo tree stands beside the stone entry staircase. According to legend, the tree has stood there since the founding of the shrine circa 1063. The tree is nicknamed kakure-ichō (hiding ginkgo), because of an Edo period legend in which shōgun Minamoto no Sanetomo was assassinated in 1219 by his nephew, Kugyō, who had hidden behind the tree to ambush the shōgun. Modern scholarship has established that ginkgos arrived from China in the 14th century, and a 1990 tree-ring measurement indicated the kakure-ichō's age to be about 500 years. On 10 March 2010, the tree blew down in a storm, but the stump has since sprouted vigorously.
Sources: en.wikipedia.org
=== Use of multi-amino acid scores === While the DIAAS has come to supersede the PDCAAS as the measurement of choice, the original recommendation of the FAO when proposing the DIAAS was that each essential amino acid be treated as a separate nutrient. This would eliminate the need to consider protein content or quality, and would arguably simplify the analysis of the nutrition of meals rather than individual foods. One proposal along these lines is the EAA-9 score, which would measure the percent of RDI of the limiting amino acid of a serving of food. These would be used to determine the EAA-9 Equivalence Serving, or the amount of a food necessary to provide the same amount of that amino acid as an egg.
On March 21, 1991, a Royal Saudi Air Force C-130H crashed in heavy smoke due to the Kuwaiti oil fires on approach to Ras Mishab Airport, Saudi Arabia. 92 Senegalese soldiers and 6 Saudi crew members were killed, the largest accident among Coalition forces. The smoke screening was also used by Iraqi anti-armor forces to a successful extent in the Battle of Phase Line Bullet, having aided in achieving the element of surprise against advancing Bradley IFVs, along with increasing the general fog of war. The fires burned out of control because of the dangers of sending in firefighting crews during the war. Land mines had been placed in areas around the oil wells and military demining was necessary before the fires could be put out. Around 5 million barrels (790,000 m3) of oil were lost each day. Eventually, privately contracted crews extinguished the fires, at a total cost of US$1.5 billion to Kuwait. By that time, however, the fires had burned for approximately ten months, causing widespread pollution. The fires have been linked with what was later deemed Gulf War syndrome, a chronic disorder afflicting military veterans and civilian workers that include fatigue, muscle pain, and cognitive problems; however, studies have indicated that the firemen who capped the wells did not report any of the symptoms that the soldiers experienced. The cause of Gulf War syndrome has since been ascribed to Sarin nerve agent.
=== Tau hypothesis of alzheimer's disease === The tau hypothesis states that excessive or abnormal phosphorylation of tau results in the transformation of normal adult tau into paired-helical-filament (PHF) tau and neurofibrillary tangles (NFTs). The stage of the disease determines NFTs' phosphorylation. In AD, at least 19 amino acids are phosphorylated; pre-NFT phosphorylation occurs at serine 199, 202 and 409, while intra-NFT phosphorylation happens at serine 396 and threonine 231. Through its isoforms and phosphorylation, tau protein interacts with tubulin to stabilize microtubule assembly. All of the six tau isoforms are present in an often hyperphosphorylated state in paired helical filaments (PHFs) in the AD brain. Tau mutations have many consequences, including microtubule dysfunction and alteration of the expression level of tau isoforms. Mutations that alter function and isoform expression of tau lead to hyperphosphorylation. The process of tau aggregation in the absence of mutations is not known but might result from increased phosphorylation, protease action or exposure to polyanions, such as glycosaminoglycans. Hyperphosphorylated tau disassembles microtubules and sequesters normal tau, MAPT 1 (microtubule associated protein tau 1), MAPT 2 and ubiquitin into tangles of PHFs. This insoluble structure damages cytoplasmic functions and interferes with axonal transport, which can lead to cell death. Hyperphosphorylated forms of tau protein are the main component of PHFs of NFTs in the brain of AD patients.
== Early life == Elizabeth Wettlaufer was born and raised in Zorra Township, a rural community near Woodstock, Ontario. Growing up in a staunchly Baptist household, she went on to earn a bachelor's degree in religious education counseling from London Baptist Bible College after graduating from Huron Park Secondary School in the mid-1980s. Wettlaufer then studied nursing at Conestoga College.
==== Calcium and phospholipids ==== Calcium and phospholipids (constituents of platelet membrane) are required for the tenase and prothrombinase complexes to function. Calcium mediates the binding of the complexes via the terminal gamma-carboxy residues on Factor Xa and Factor IXa to the phospholipid surfaces expressed by platelets, as well as procoagulant microparticles or microvesicles shed from them. Calcium is also required at other points in the coagulation cascade. Calcium ions play a major role in the regulation of coagulation cascade that is paramount in the maintenance of hemostasis. Other than platelet activation, calcium ions are responsible for complete activation of several coagulation factors, including coagulation Factor XIII.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.